Effect of Helicobacter pylori eradication on hepatic steatosis, NAFLD fibrosis score and HSENSI in patients with nonalcoholic steatohepatitis: A MR imaging-based pilot open-label study;O efeito da erradicação do Helicobacter pylori na esteatose hepática, no escore de fibrose na DHNA e o HSENSI em pacientes com esteatohepatite não alcoólica: Um estudo piloto aberto baseado em ressonância magnética

Arquivos de Gastroenterologia

Volumn 51, Issue 3, 2014, Pages 261-268

  Polyzos, Stergios A ^a   Nikolopoulos, Panagiotis ^b   Stogianni, Angeliki ^c   Romiopoulos, Iordanis ^a   Katsinelos, Panagiotis ^a   Kountouras, Jannis ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b 424 General Army Hospital   (Greece)

^c Ippokration Hospital   (Greece)

Author keywords

Fatty liver; Helicobacter pylori; Magnetic resonance imaging

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; AMOXICILLIN; CARBON 13; CLARITHROMYCIN; CREATINE KINASE; CREATININE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LEVOFLOXACIN; LOW DENSITY LIPOPROTEIN; METRONIDAZOLE; OMEPRAZOLE; TRIACYLGLYCEROL; URIC ACID; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL CLEARANCE; BODY MASS; BREATH ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ERADICATION THERAPY; ERYTHROCYTE SEDIMENTATION RATE; FAT CONTENT; FATTY LIVER; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIP CIRCUMFERENCE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; NONALCOHOLIC STEATOHEPATITIS INDEX; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PILOT STUDY; SCORING SYSTEM; UREA BREATH TEST; WAIST CIRCUMFERENCE; WAIST HIP RATIO; BLOOD; COMPLICATION; HELICOBACTER INFECTIONS; MICROBIOLOGY; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX;

ADULT; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; PILOT PROJECTS; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84925223662     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/S0004-28032014000300017     Document Type: Article

References (29)

1. Alkhouri N, Morris-Stiff G, Campbell C, Lopez R, Tamimi TA, Yerian L, et al. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2012;32:297-302.
2. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-54.
3. Bae JC, Rhee EJ, Lee WY, Park SE, Park CY, Oh KW, et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care. 2011;34:727-9.
4. Banic M, Franceschi F, Babic Z, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter. 2012;17 Suppl 1:49-55.
5. Cali AM, De Oliveira AM, Kim H, Chen S, Reyes-Mugica M, Escalera S, et al. Glucose dysregulation and hepatic steatosis in obese adolescents: is there a link? Hepatology. 2009;49:1896-903.
6. Cassidy FH, Yokoo T, Aganovic L, Hanna RF, Bydder M, Middleton MS, et al. Fatty liver disease: MR imaging techniques for the detection and quantification of liver steatosis. Radiographics. 2009;29:231-60.
7. Cesbron-Metivier E, Roullier V, Boursier J, Cavaro-Menard C, Lebigot J, Michalak S, et al. Noninvasive liver steatosis quantification using MRI techniques combined with blood markers. Eur J Gastroenterol Hepatol. 2010;22:973-82.
8. Chen SH, He F, Zhou HL, Wu HR, Xia C, Li YM. Relationship between nonalcoholic fatty liver disease and metabolic syndrome. J Dig Dis. 2011;12:125-30.
9. Cindoruk M, Cirak MY, Unal S, Karakan T, Erkan G, Engin D, et al. Identification of Helicobacter species by 16S rDNA PCR and sequence analysis in human liver samples from patients with various etiologies of benign liver diseases. EurJ Gastroenterol Hepatol. 2008;20:33-6.
10. d' Assignies G, Fontés G, Kauffmann C, Latour M, Gaboury L, Boulanger Y, et al. Early detection of liver steatosis by magnetic resonance imaging in rats infused with glucose and intralipid solutions and correlation to insulin levels. Metabolism. 2013;62:1850-7.
11. Figura N, Franceschi F, Santucci A, Bernardini G, Gasbarrini G, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter. 2010;15 Suppl 1:60-8.
12. Jamali R, Mofid A, Vahedi H, Farzaneh R, Dowlatshahi S. The effect of helicobacter pylori eradication on liver fat content in subjects with non-alcoholic Fatty liver disease: a randomized open-label clinical trial. Hepat Mon. 2013;13:e14679.
13. Kleiner DE, Brunt EM, Van NM, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-21.
14. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137:865-72.
15. Kountouras J, Zavos C, Chatzopoulos D. A concept on the role of Helicobacter pylori infection in autoimmune pancreatitis. J Cell Mol Med. 2005;9:196-207.
16. Lee YJ, Lee HR, Shim JY, Moon BS, Lee JH, Kim JK. Relationship between white blood cell count and nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42: 888-94.
17. Pirouz T, Zounubi L, Keivani H, Rakhshani N, Hormazdi M. Detection of Helicobacter pylori in paraffin-embedded specimens from patients with chronic liver diseases, using the amplification method. Dig Dis Sci. 2009;54:1456-9.
18. Polyzos SA, Kountouras J, Deretzi G, Zavos C, Mantzoros CS. The emerging role of endocrine disruptors in pathogenesis of insulin resistance: a concept implicating nonalcoholic fatty liver disease. Curr Mol Med. 2012;12:68-82.
19. Polyzos SA, Kountouras J, Papatheodorou A, Patsiaoura K, Katsiki E, Zafeiriadou E, et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism. 2013;62:121-6.
20. Polyzos SA, Kountouras J, Slavakis A, Zafeiriadou E, Patsiaoura K, Katsiki E, et al. A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study. Biomarkers. 2013;18:607-13.
21. Polyzos SA, Kountouras J, Zavos C. The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in nonalcoholic fatty liver disease. Hippokratia. 2009;13:127.
22. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med. 2009;72:299-314.
23. Polyzos SA, Kountouras J, Zavos C, Deretzi G. The association between Helicobacter pylori infection and insulin resistance: A systematic review. Helicobacter. 2011;16:79-88.
24. Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic fatty liver disease: Multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol. 2012;46:272-84.
25. Polyzos SA, Mantzoros CS. Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism. 2014;63:161-7.
26. Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol. 2013;28:68-76.
27. Suzuki H, Franceschi F, Nishizawa T, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter. 2011;16 Suppl 1:65-9.
28. Takuma Y. Helicobacter pylori infection and liver diseases. Gan To Kagaku Ryoho. 2011;38:362-4.
29. Zhou X, Zhang C, Wu J, Zhang G. Association between Helicobacter pylori infection and diabetes mellitus: a meta-analysis of observational studies. Diabetes Res Clin Pract. 2013;99:200-8.